Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Utilizing Monocarboxylate Transporter 1-Mediated Blood–Brain Barrier Penetration for Glioblastoma Positron Emission Tomography Imaging with 6-[18F]Fluoronicotinic Acid

Dillemuth, Pyry; Ayo, Abiodun; Airenne, Tomi T.; Lövdahl, Petter; Bakay, Emel; Zhuang, Xiaoqing; Liljenbäck, Heidi; Paunonen, Sami Tuomas; Kunnas, Jonne; Filppu, Pauliina; Rajander, Johan; Johnson, Mark S.; Roivainen, Anne; Salminen, Tiina A.; Rosenholm, Jessica M.; Laakkonen, Pirjo; Li, Xiang-Guo

Utilizing Monocarboxylate Transporter 1-Mediated Blood–Brain Barrier Penetration for Glioblastoma Positron Emission Tomography Imaging with 6-[18F]Fluoronicotinic Acid

Dillemuth, Pyry
Ayo, Abiodun
Airenne, Tomi T.
Lövdahl, Petter
Bakay, Emel
Zhuang, Xiaoqing
Liljenbäck, Heidi
Paunonen, Sami Tuomas
Kunnas, Jonne
Filppu, Pauliina
Rajander, Johan
Johnson, Mark S.
Roivainen, Anne
Salminen, Tiina A.
Rosenholm, Jessica M.
Laakkonen, Pirjo
Li, Xiang-Guo
Katso/Avaa
dillemuth-et-al-2025-utilizing-monocarboxylate-transporter-1-mediated-blood-brain-barrier-penetration-for-glioblastoma(1).pdf (10.78Mb)
Lataukset: 

American Chemical Society (ACS)
doi:10.1021/acs.molpharmaceut.5c00457
URI
https://doi.org/10.1021/acs.molpharmaceut.5c00457
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2025082785702
Tiivistelmä

Glioblastoma is the most malignant brain tumor in adults, and its prognosis remains dismal. The blood–brain barrier impedes the effectiveness of many drugs, which are otherwise effective for cancer treatment. Monocarboxylate transporter 1 (MCT1) is expressed on endothelial and glioblastoma cells. Our approach aims to leverage MCT1 to transport theranostic agents across the blood–brain barrier. In this context, we present herein the application of fluorine-18-labeled nicotinic acid (denoted as [18F]FNA) for glioblastoma imaging using positron emission tomography (PET). An intracranial mouse model of human glioblastoma was prepared by using patient-derived BT12 cells. PET imaging, ex vivo biodistribution, brain tissue autoradiography, and tumor and tissue uptake kinetic analyses were performed. Additionally, the ligand–target interaction was studied using in silico modeling. The xenografted glioblastomas were distinctly visualized in all 18 mice with a mean standardized uptake value of 0.92 ± 0.11 and tumor-to-brain ratio of 1.66 ± 0.17. The tumor uptake of intravenously administered [18F]FNA decreased by 76% on average when MCT1 was inhibited, whereas preadministration of 60 mg/kg niacin significantly enhanced [18F]FNA tumor uptake. The G protein-coupled receptor GPR109A is a high-affinity receptor for niacin (nicotinic acid). In silico simulations indicated that both niacin and fluorinated nicotinic acid (FNA) interact with the GPR109A receptor in a similar manner. In the presence of a GPR109A inhibitor in in vivo experiments, the tumor residence of [18F]FNA was extended. [18F]FNA has demonstrated its potential for PET imaging in a clinically relevant orthotopic glioblastoma model, and MCT1 plays a crucial role in [18F]FNA transport. The results pave the way for the development of niacin-derived theranostics for glioblastoma care.

Kokoelmat
  • Rinnakkaistallenteet [29335]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste